Corindus Vascular Robotics (CVRS) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Corindus Vascular Robotics (CVRS) PT Raised to $2 at Ladenburg Thalmann
March 13, 2019 9:18 AM EDTLadenburg Thalmann analyst Jeffrey Cohen raised the price target on Corindus Vascular Robotics (NYSE: CVRS) to $2.00 (from $1.70) while maintaining a Buy rating following the company's 4Q. Revenue, net loss, and loss per share for the quarter was $4.7 million, $7.4 million, and $0.04. Consensus estimate for the quarter were... More
